Abstract：
Liquid biopsy is a minimally invasive method for biomarkers detection in body fluids, particularly in blood, which offers an elevated and growing number of clinical applications in oncology. As a result of the improvement in the techniques for DNA analysis, above all next-generation sequencing (NGS) assays, circulating tumor DNA (ctDNA) has become the most informing tumor-derived material for most types of cancer, including non-small cell lung cancer (NSCLC). Although ctDNA concentration is higher in patients with advanced tumors, it can be detected even in patients with early-stage disease. Therefore, numerous clinical applications of ctDNA in the management of early-stage lung cancer are emerging, such as lung cancer screening, the identification of minimal residual disease (MRD), and the prediction of relapse before radiologic progression. Moreover, a high number of clinical trials are ongoing to better define the impact of ctDNA evaluation in this setting. Aim of this review is to offer a comprehensive overview of the most relevant implementations in using ctDNA for the management of early-stage lung cancer, addressing available data, technical aspects, limitations, and future perspectives.
摘要：
液体活检是一种用于体液中生物标志物检测的微创方法，特别是在血液中，在肿瘤学中提供了越来越多的临床应用。由于DNA分析技术的改进，最重要的是下一代测序（NGS）测定，循环肿瘤DNA（ctDNA）已成为大多数类型癌症的最有意义的肿瘤来源材料，包括非小细胞肺癌（NSCLC）。尽管晚期肿瘤患者的ctDNA浓度较高，即使在早期疾病患者中也可以检测到。因此,ctDNA在早期肺癌治疗中的许多临床应用正在出现，比如肺癌筛查，微小残留病(MRD)的鉴定，以及放射学进展前复发的预测。此外，目前正在进行大量临床试验,以更好地定义ctDNA评估在这种情况下的影响.这篇综述的目的是全面概述使用ctDNA管理早期肺癌的最相关实施方式，寻址可用数据，技术方面,局限性,和未来的前景。
